Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05366413 · ClinicalTrials.gov registry record · NA

Early Interventional Treatment for Cancer Pain

A NA study of Cancer Pain, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
30
Enrollment target
2
Study locations

NCT05366413 is a NA study of Cancer Pain that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants, below the 160-participant average among 15 other Cancer Pain trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05366413, a NA study of Cancer Pain, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

The purpose of the study is to evaluate how feasible and beneficial it is to refer patients with cancer pain to a doctor who specializes in pain management, including procedures to relieve pain, and whether this is helpful to patients with pain related to their cancer.

Conditions Studied

Interventions

  • OTHER Early Referral
  • OTHER Pain Management Strategies

Study Locations (2)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-06-02
Est. Completion 2024-10-26
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT05366413

The ClinicalTrials.gov registry entry for NCT05366413 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 160-participant average among 15 other Cancer Pain trials with a reported enrollment target (81% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer Pain appearing as the primary indexed condition, and to 2 interventions - of which Early Referral is the first listed.

NCT05366413 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05366413 about?

NCT05366413 is a clinical study titled "Early Interventional Treatment for Cancer Pain". The purpose of the study is to evaluate how feasible and beneficial it is to refer patients with cancer pain to a doctor who specializes in pain management, including procedures to relieve pain, and whether this is helpful to patients with pain related to their cancer.

What is the current status of trial NCT05366413?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2022-06-02. Estimated completion is 2024-10-26.

What conditions does trial NCT05366413 study?

This clinical trial studies the following conditions: Cancer Pain.

What interventions are being tested in trial NCT05366413?

The interventions under investigation include: Early Referral (OTHER), Pain Management Strategies (OTHER).

Who is sponsoring clinical trial NCT05366413?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05366413 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.